8. Huntington disease Clinical trials / Disease details


Clinical trials : 229 Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01411163
(ClinicalTrials.gov)
April 20104/8/2011Premanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityPremanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityHuntington's DiseaseDrug: Creatine monohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Completed26 YearsN/ABoth24Phase 2United States
2NCT00712426
(ClinicalTrials.gov)
September 20098/7/2008Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Huntington's DiseaseDrug: Creatine Monohydrate;Drug: PlaceboMassachusetts General HospitalUniversity of Rochester;National Center for Complementary and Integrative Health (NCCIH)Terminated18 YearsN/ABoth553Phase 3United States;Australia;Canada;New Zealand
3NCT01411150
(ClinicalTrials.gov)
May 20094/8/2011Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyPremanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyHuntington's DiseaseDrug: Creatine MonohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Completed26 YearsN/ABoth38Phase 2United States
4NCT00592995
(ClinicalTrials.gov)
December 200728/12/2007Creatine Safety and Tolerability in Premanifest HD: PRECRESTCreatine Safety and Tolerability in Premanifest HD: PRECRESTHuntington DiseaseDrug: Creatine monohydrate;Drug: PlaceboMassachusetts General HospitalNULLCompleted26 YearsN/ABoth64Phase 2United States
5NCT01412151
(ClinicalTrials.gov)
April 20055/8/2011Creatine Safety & Tolerability in Huntington's DiseaseCreatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HDHuntington's Disease (HD)Drug: Creatine monohydrateMassachusetts General HospitalNULLCompleted18 YearsN/AAll10Phase 2United States
6NCT00026988
(ClinicalTrials.gov)
October 200115/11/2001Creatine Therapy for Huntington's DiseaseCreatine Therapy for Huntington's DiseaseHuntington's DiseaseDrug: CreatineNational Center for Complementary and Integrative Health (NCCIH)NULLCompleted18 YearsN/ABoth64Phase 1/Phase 2United States